Cover Image

EFFECT OF NEOADJUVANT CHEMOTHERAPY ON HORMONE RECEPTOR (ER, PR) STATUS AND HER-2/NEU EXPRESSION IN INDIAN BREAST CANCER PATIENTS: A PROSPECTIVE STUDY

Main Author: Saumya Singh , Vaibhav Jaiswal , Anand Kumar Mishra and Sandeep Tewari.
Format: Article eJournal
Terbitan: , 2019
Subjects:
Neoadjuvant Chemotherapy Hormone Receptor Immunohistochemistry Cancer Breast
Online Access: https://zenodo.org/record/3452023
ctrlnum 3452023
fullrecord <?xml version="1.0"?> <dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><creator>Saumya Singh , Vaibhav Jaiswal , Anand Kumar Mishra and Sandeep Tewari.</creator><date>2019-08-25</date><description>Objective: This study was aimed to evaluate whether neoadjuvant chemotherapy (NACT) changes hormone receptor (ER, PR) status, Her-2/neu expression in carcinoma breast and role of outcome in planning adjuvant chemotherapy. Methods: 71 patients of locally advanced breast cancer (LABC), receiving NACT, were included. Core biopsy was done, to confirm invasive cancer, ER, PR and Her-2/neu expression before commencing NACT. Post treatment mastectomy specimen was analyzed for histopathology, ER, PR and Her-2/neu expression. Results: Immunohistochemistry (IHC) showed that ER positivity changed from 29.6% (n=21) to 28.2% (n=20) after treatment. While 70.4% (n=50) were ER- before treatment which increased to 71.8% (n=51) post chemotherapy (p=0.99). Pre-NACT, PR was positive in 31.0% (n=22) which changed to 28.2% (n=20) after treatment. 69% (n=49) were PR before treatment which increased to 71.8% (n=51) post chemotherapy (p=0.99). Her-2/neu was positive in 71.8% (n=51) before treatment which became 70.4% (n=50) post-treatment (P= 0.88). 26.8% were ER+ PR+ (n=19), 66.2% were ER-PR- (n=47), 4.2% were ER-PR+ (n=2) before NACT. Change in expression of hormone receptor status was noticed, ER+PR+ decreased to 25.4% (n=18), ER-PR- increased to 69.0% (n=49), ER-PR + decreased to 2.8% (n=2), no change was noticed in ER+PR- status. Tumor size was significantly reduced from pretreatment (39.37? 10.63 cms) to post-treatment (23.87?7.51 cms) (p &lt; 0.05). Conclusion: On the basis of this study it was concluded that ER, PR and Her-2/neu status changes on IHC staining after NACT. So, IHC analysis on a post treatment tissue block should be repeated before planning adjuvant chemotherapy in patients of carcinoma breast.</description><identifier>https://zenodo.org/record/3452023</identifier><identifier>10.5281/zenodo.3452023</identifier><identifier>oai:zenodo.org:3452023</identifier><relation>doi:10.5281/zenodo.3452022</relation><rights>info:eu-repo/semantics/openAccess</rights><rights>https://creativecommons.org/licenses/by/4.0/legalcode</rights><subject>Neoadjuvant Chemotherapy Hormone Receptor Immunohistochemistry Cancer Breast.</subject><title>EFFECT OF NEOADJUVANT CHEMOTHERAPY ON HORMONE RECEPTOR (ER, PR) STATUS AND HER-2/NEU EXPRESSION IN INDIAN BREAST CANCER PATIENTS: A PROSPECTIVE STUDY.</title><type>Journal:Article</type><type>Journal:Article</type><recordID>3452023</recordID></dc>
format Journal:Article
Journal
Journal:eJournal
author Saumya Singh , Vaibhav Jaiswal , Anand Kumar Mishra and Sandeep Tewari.
title EFFECT OF NEOADJUVANT CHEMOTHERAPY ON HORMONE RECEPTOR (ER, PR) STATUS AND HER-2/NEU EXPRESSION IN INDIAN BREAST CANCER PATIENTS: A PROSPECTIVE STUDY
publishDate 2019
topic Neoadjuvant Chemotherapy Hormone Receptor Immunohistochemistry Cancer Breast
url https://zenodo.org/record/3452023
contents Objective: This study was aimed to evaluate whether neoadjuvant chemotherapy (NACT) changes hormone receptor (ER, PR) status, Her-2/neu expression in carcinoma breast and role of outcome in planning adjuvant chemotherapy. Methods: 71 patients of locally advanced breast cancer (LABC), receiving NACT, were included. Core biopsy was done, to confirm invasive cancer, ER, PR and Her-2/neu expression before commencing NACT. Post treatment mastectomy specimen was analyzed for histopathology, ER, PR and Her-2/neu expression. Results: Immunohistochemistry (IHC) showed that ER positivity changed from 29.6% (n=21) to 28.2% (n=20) after treatment. While 70.4% (n=50) were ER- before treatment which increased to 71.8% (n=51) post chemotherapy (p=0.99). Pre-NACT, PR was positive in 31.0% (n=22) which changed to 28.2% (n=20) after treatment. 69% (n=49) were PR before treatment which increased to 71.8% (n=51) post chemotherapy (p=0.99). Her-2/neu was positive in 71.8% (n=51) before treatment which became 70.4% (n=50) post-treatment (P= 0.88). 26.8% were ER+ PR+ (n=19), 66.2% were ER-PR- (n=47), 4.2% were ER-PR+ (n=2) before NACT. Change in expression of hormone receptor status was noticed, ER+PR+ decreased to 25.4% (n=18), ER-PR- increased to 69.0% (n=49), ER-PR + decreased to 2.8% (n=2), no change was noticed in ER+PR- status. Tumor size was significantly reduced from pretreatment (39.37? 10.63 cms) to post-treatment (23.87?7.51 cms) (p < 0.05). Conclusion: On the basis of this study it was concluded that ER, PR and Her-2/neu status changes on IHC staining after NACT. So, IHC analysis on a post treatment tissue block should be repeated before planning adjuvant chemotherapy in patients of carcinoma breast.
id IOS17403.3452023
institution Universitas PGRI Palembang
institution_id 189
institution_type library:university
library
library Perpustakaan Universitas PGRI Palembang
library_id 587
collection Marga Life in South Sumatra in the Past: Puyang Concept Sacrificed and Demythosized
repository_id 17403
city KOTA PALEMBANG
province SUMATERA SELATAN
repoId IOS17403
first_indexed 2022-07-26T01:25:07Z
last_indexed 2022-07-26T01:25:07Z
recordtype dc
_version_ 1739406510234009600
score 17.538404

Lihat Juga